306 related articles for article (PubMed ID: 21677141)
1. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype.
Lahoud MH; Ahmet F; Kitsoulis S; Wan SS; Vremec D; Lee CN; Phipson B; Shi W; Smyth GK; Lew AM; Kato Y; Mueller SN; Davey GM; Heath WR; Shortman K; Caminschi I
J Immunol; 2011 Jul; 187(2):842-50. PubMed ID: 21677141
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice.
Caminschi I; Vremec D; Ahmet F; Lahoud MH; Villadangos JA; Murphy KM; Heath WR; Shortman K
Mol Immunol; 2012 Feb; 50(1-2):9-17. PubMed ID: 22209163
[TBL] [Abstract][Full Text] [Related]
3. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes.
Macri C; Dumont C; Panozza S; Lahoud MH; Caminschi I; Villadangos JA; Johnston AP; Mintern JD
Mol Immunol; 2017 Jan; 81():143-150. PubMed ID: 27978488
[TBL] [Abstract][Full Text] [Related]
5. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
Schreibelt G; Klinkenberg LJ; Cruz LJ; Tacken PJ; Tel J; Kreutz M; Adema GJ; Brown GD; Figdor CG; de Vries IJ
Blood; 2012 Mar; 119(10):2284-92. PubMed ID: 22234694
[TBL] [Abstract][Full Text] [Related]
6. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
[TBL] [Abstract][Full Text] [Related]
7. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.
Zeng B; Middelberg AP; Gemiarto A; MacDonald K; Baxter AG; Talekar M; Moi D; Tullett KM; Caminschi I; Lahoud MH; Mazzieri R; Dolcetti R; Thomas R
J Clin Invest; 2018 May; 128(5):1971-1984. PubMed ID: 29485973
[TBL] [Abstract][Full Text] [Related]
8. Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes.
Schloss J; Ali R; Babad J; Guerrero-Ros I; Pongsachai J; He LZ; Keler T; DiLorenzo TP
Immunohorizons; 2019 Jun; 3(6):236-253. PubMed ID: 31356169
[TBL] [Abstract][Full Text] [Related]
9. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
10. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
11. In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.
Hesse C; Ginter W; Förg T; Mayer CT; Baru AM; Arnold-Schrauf C; Unger WW; Kalay H; van Kooyk Y; Berod L; Sparwasser T
Eur J Immunol; 2013 Oct; 43(10):2543-53. PubMed ID: 23784881
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
13. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
[TBL] [Abstract][Full Text] [Related]
14. Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall.
Kato Y; Zaid A; Davey GM; Mueller SN; Nutt SL; Zotos D; Tarlinton DM; Shortman K; Lahoud MH; Heath WR; Caminschi I
J Immunol; 2015 Aug; 195(3):1006-14. PubMed ID: 26101322
[TBL] [Abstract][Full Text] [Related]
15. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.
Yan Z; Wu Y; Du J; Li G; Wang S; Cao W; Zhou X; Wu C; Zhang D; Jing X; Li Y; Wang H; Gao Y; Qi Y
Oncotarget; 2016 Jun; 7(26):40437-40450. PubMed ID: 27250027
[TBL] [Abstract][Full Text] [Related]
16. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
[TBL] [Abstract][Full Text] [Related]
17. Enhanced dendritic cell-induced immune responses mediated by the novel C-type lectin receptor mDCAR1.
Kaden SA; Kurig S; Vasters K; Hofmann K; Zaenker KS; Schmitz J; Winkels G
J Immunol; 2009 Oct; 183(8):5069-78. PubMed ID: 19786536
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
19. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.
You Z; Huang XF; Hester J; Rollins L; Rooney C; Chen SY
J Immunol; 2000 Oct; 165(8):4581-91. PubMed ID: 11035100
[TBL] [Abstract][Full Text] [Related]
20. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
